Stock Scorer

Rocket Pharmaceuticals, Inc. (RCKT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -49.6M Q4 '21: -44.3M Q1 '22: -42.6M Q2 '22: -54.2M Q3 '22: -58.5M Q4 '22: -69.1M Q1 '23: -62.2M Q2 '23: -68.8M Q3 '23: -65.4M Q4 '23: -63.3M Q1 '24: -67.4M Q2 '24: -73.7M Q3 '24: -69.4M Q4 '24: -62.7M Q1 '25: -64.4M Q2 '25: -71.1M Q3 '25: -52.2M Q4 '25: -44M Q1 '26: -48.5M Q2 '26: -46.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-100M -50M 0 50M 100M 150M Q3 '21: -50.1M Q4 '21: -44.2M Q1 '22: -43M Q2 '22: -54.4M Q3 '22: -57.8M Q4 '22: -66.7M Q1 '23: -58.3M Q2 '23: -65.7M Q3 '23: -61.9M Q4 '23: -59.7M Q1 '24: -62.1M Q2 '24: -69.6M Q3 '24: -66.7M Q4 '24: -60.3M Q1 '25: -61.3M Q2 '25: -68.9M Q3 '25: -50.3M Q4 '25: -42.5M Q1 '26: -47.6M Q2 '26: 123.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -27.4M Q4 '21: -30.9M Q1 '22: -39.2M Q2 '22: -39M Q3 '22: -43.9M Q4 '22: -56M Q1 '23: -57.6M Q2 '23: -50.9M Q3 '23: -57.1M Q4 '23: -29.3M Q1 '24: -56.9M Q2 '24: -53.8M Q3 '24: -52.1M Q4 '24: -46.9M Q1 '25: -55.8M Q2 '25: -49M Q3 '25: -50.4M Q4 '25: -34.8M Q1 '26: -45.4M Q2 '26: -39.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -31.3M Q4 '21: -32.9M Q1 '22: -41.2M Q2 '22: -41.9M Q3 '22: -44.4M Q4 '22: -59M Q1 '23: -60.6M Q2 '23: -55M Q3 '23: -61.8M Q4 '23: -34M Q1 '24: -58.9M Q2 '24: -55.8M Q3 '24: -53.7M Q4 '24: -47.3M Q1 '25: -56.2M Q2 '25: -49M Q3 '25: -50.5M Q4 '25: -34.9M Q1 '26: -45.5M Q2 '26: -39.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q1 '20: 54.9M Q2 '20: 55.2M Q3 '20: 55.2M Q1 '21: 61.6M Q2 '21: 63.1M Q3 '21: 63.8M Q1 '22: 64.5M Q2 '22: 65.5M Q3 '22: 66.2M Q1 '23: 79.5M Q2 '23: 80.5M Q3 '23: 82.6M Q1 '24: 93.5M Q2 '24: 93.7M Q3 '24: 94.2M Q1 '25: 110.1M Q2 '25: 111M Q3 '25: 111.6M Q1 '26: 112.1M Q2 '26: 114.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '21: -3.08 Q4 '21: -2.67 Q1 '22: -2.69 Q2 '22: -2.97 Q3 '22: -3.05 Q4 '22: -3.26 Q1 '23: -3.32 Q2 '23: -3.31 Q3 '23: -3.19 Q4 '23: -2.92 Q1 '24: -2.85 Q2 '24: -2.77 Q3 '24: -2.73 Q4 '24: -2.73 Q1 '25: -2.63 Q2 '25: -2.51 Q3 '25: -2.25 Q4 '25: -2.01 Q1 '26: -1.87 Q2 '26: -0.17 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for RCKT: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.